But the new report found that psychotherapists are often ill-equipped to spot these cases. When questioned, most clinicians ...

A new binational study of 259 outpatient psychotherapists across Canada and the United States highlights significant gaps in ...

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splici ...

Muscle ultrasound has emerged as a pivotal, non‐invasive imaging modality that offers real‐time insights into muscle structure and pathology. This technique enables both qualitative and quantitative ...

Researchers have made a significant finding in determining the genetic background of dilated cardiomyopathy in Dobermanns. This research helps us understand the genetic risk factors related to fatal ...

Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...

Biomedical engineers have grown muscles in a lab to better understand and test treatments for a group of extremely rare muscle disorders called dysferlinopathy or limb girdle muscular dystrophies 2B ...

A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative method known as TEVs-TTN, for studying the specific mechanical functions of proteins through their ...